Related Experiment Video
Updated: May 28, 2026
Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
Published on: February 21, 2019
Structural characterization of inhibitor complexes with checkpoint kinase 2 (Chk2), a drug target for cancer therapy
George T Lountos1, Andrew G Jobson, Joseph E Tropea
1Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702-1201, USA.
Abstract:
Chk2 (checkpoint kinase 2) is a serine/threonine kinase that participates in a series of signaling networks responsible for maintaining genomic integrity and responding to DNA damage. The development of selective Chk2 inhibitors has recently attracted much interest as a means of sensitizing cancer cells to current DNA-damaging agents used in the treatment of cancer. Additionally, selective Chk2 inhibitors may reduce p53-mediated apoptosis in normal tissues, thereby helping to mitigate adverse side effects from chemotherapy and radiation. Thus far, relatively few selective inhibitors of Chk2 have been described and none have yet progressed into clinical trials. Here, we report crystal structures of the catalytic domain of Chk2 in complex with a novel series of potent and selective small molecule inhibitors. These compounds exhibit nanomolar potencies and are selective for Chk2 over Chk1. The structures reported here elucidate the binding modes of these inhibitors to Chk2 and provide information that can be exploited for the structure-assisted design of novel chemotherapeutics.
Insights
New Chk2 inhibitors show promise for cancer therapy. These selective compounds, detailed by crystal structures, may enhance chemotherapy effectiveness and reduce side effects by targeting genomic integrity pathways.
Area of Science:
- Molecular Biology
- Cancer Research
- Structural Biology
Background:
- Checkpoint kinase 2 (Chk2) is crucial for maintaining genomic integrity and DNA damage response.
- Selective Chk2 inhibitors are of interest for sensitizing cancer cells to DNA-damaging agents and mitigating chemotherapy side effects.
Purpose of the Study:
- To report novel potent and selective small molecule inhibitors of Chk2.
- To elucidate the binding modes of these inhibitors to the Chk2 catalytic domain through crystal structures.
Main Methods:
- X-ray crystallography was used to determine the structures of the Chk2 catalytic domain in complex with novel inhibitors.
- Biochemical assays were employed to assess inhibitor potency and selectivity.
Main Results:
- Novel Chk2 inhibitors with nanomolar potencies were identified.
- These inhibitors demonstrated selectivity for Chk2 over Chk1.
- Crystal structures revealed the binding interactions of these inhibitors with the Chk2 catalytic domain.
Conclusions:
- The identified Chk2 inhibitors represent promising candidates for cancer therapeutics.
- The elucidated binding modes provide a basis for structure-assisted design of improved Chk2 inhibitors.
- Further development could lead to novel chemotherapeutics with enhanced efficacy and reduced toxicity.
More Related Videos
Related Concept Videos
02:34Inhibition of Cdk Activity
02:34Inhibition of CDK Activity
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
01:31The Intrinsic Apoptotic Pathway